Limited Uptake of Hepatitis C Treatment Among Injection Drug Users
- 965 Downloads
We characterized hepatitis C virus (HCV) treatment knowledge, experience and barriers in a cohort of community-based injection drug users (IDUs) in Baltimore, MD. In 2005, a questionnaire on HCV treatment knowledge, experience and barriers was administered to HCV-infected IDUs. Self-reported treatment was confirmed from medical records. Of 597 participants, 71% were male, 95% African-American, 31% HIV co-infected and 94% were infected with HCV genotype 1; 70% were aware that treatment was available, but only 22% understood that HCV could be cured. Of 418 who had heard of treatment, 86 (21%) reported an evaluation by a provider that included a discussion of treatment of whom 30 refused treatment, 20 deferred and 36 reported initiating treatment (6% overall). The most common reasons for refusal were related to treatment-related perceptions and a low perceived need of treatment. Compared to those who had discussed treatment with their provider, those who had not were more likely to be injecting drugs, less likely to have health insurance, and less knowledgeable about treatment. Low HCV treatment effectiveness was observed in this IDU population. Comprehensive integrated care strategies that incorporate education, case-management and peer support are needed to improve care and treatment of HCV-infected IDUs.
KeywordsHepatitis C virus Injection drug use Antiviral therapy Health care access
The authors acknowledge Lisa McCall for project management, Charles Spoler for HCV counseling, Melody Schaeffer for chart abstraction, and the ALIVE study staff and participants without whom this would not have been possible. This work was supported in part by Public Health Service Grants, National Institute on Drug Abuse, DA16078, DA04334 and DA12568.
- 1.Recommendations for prevention, control of hepatitis C virus (HCV) infection and HCV-related chronic disease. (1998). Centers for disease control and prevention. Morbidity and Mortality Weekly Report, 47, 1–39.Google Scholar
- 9.NIH (2002). Consensus statement on management of hepatitis C: 2002. NIH Consensus and State-of-the-Science Statements, 19, 1–46.Google Scholar
- 18.Mehta, S. H., Thomas, D. L., Sulkowski, M. S., Safaein, M., Vlahov, D., & Strathdee, S. A. (2005). A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV/HCV-co-infected injection drug users. AIDS, 19(Suppl. 3), S179–S189.PubMedGoogle Scholar
- 26.Fishbein, D. A., Lo, Y., Reinus, J. F., Gourevitch, M. N., & Klein, R. S. (2004). Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection. Journal of Acquired Immune Deficiency Syndrome, 37, 1367–1375.CrossRefGoogle Scholar